{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T01:55:00Z","timestamp":1786758900405,"version":"build-2736575974"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2011,9,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The aims of this multicenter study were to evaluate the response rate, progression-free survival, and toxicity of the combination of bortezomib, bendamustine, and rituximab in patients with follicular lymphoma whose disease was relapsed or refractory to prior treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Patients received five 35-day cycles of bortezomib, bendamustine, and rituximab: bortezomib administered intravenously (IV) at a dose of 1.6 mg\/m<jats:sup>2<\/jats:sup>on days 1, 8, 15, and 22, cycles one to five; bendamustine 50, 70, or 90 mg\/m<jats:sup>2<\/jats:sup>IV over a 60-minute infusion on days 1 and 2, cycles one to five; and rituximab 375 mg\/m<jats:sup>2<\/jats:sup>on days 1, 8, 15, and 22 of cycle one and day 1 of subsequent cycles. Patients were assessed using the International Workshop Response Criteria, with the primary end point of 60% complete response rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy-three patients were enrolled. During the dose-escalation phase, the maximum-tolerated dose for bendamustine was not reached; the 90 mg\/m<jats:sup>2<\/jats:sup>dose level was expanded for the efficacy assessment, and a total of 63 patients received bendamustine 90 mg\/m<jats:sup>2<\/jats:sup>. In these 63 patients, the overall response rate was 88% (including 53% complete response). Median duration of response was 11.7 months (95% CI, 9.2 to 13.3). Median progression-free survival was 14.9 months (95% CI, 11.1 to 23.7). Toxicities were manageable; myelosuppression was the main toxicity (25% and 14% of patients experienced grade 3 to 4 neutropenia and grade 3 to 4 thrombocytopenia, respectively). Transient grade 3 to 4 neuropathy occurred in 11% of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination of bortezomib, bendamustine, and rituximab is highly active in patients with follicular lymphoma who have received previous treatment.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2010.32.1844","type":"journal-article","created":{"date-parts":[[2011,8,3]],"date-time":"2011-08-03T00:15:42Z","timestamp":1312330542000},"page":"3389-3395","source":"Crossref","is-referenced-by-count":88,"title":["Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study"],"prefix":"10.1200","volume":"29","author":[{"given":"Nathan","family":"Fowler","sequence":"first","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lee","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Letzer","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipinkumar","family":"Amin","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Williams","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Smith","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Saleh","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rosen","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Shi","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Parasuraman","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Nathan Fowler, MD Anderson Cancer Center, Houston, TX; Brad S. Kahl, University of Wisconsin, Madison, WI; Peter Lee and Peter Rosen, Tower Cancer Research Foundation, Beverly Hills; Alfred Saleh, Sharp Healthcare, San Diego, CA; Jeffrey V. Matous, Rocky Mountain Cancer Center, Denver, CO; Amanda F. Cashen, Washington School of Medicine, St Louis, MO; Samuel A. Jacobs, Hillman Cancer Center, Pittsburgh, PA; Jeffrey Letzer, Kalamazoo Hematology\/Oncology, Kalamazoo, MI; Bipinkumar Amin, Legacy Pharma..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2005.11.003"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"B5","unstructured":"VELCADE (bortezomib) for injection: Prescribing information 2009 12 Cambridge, MA Millennium Pharmaceuticals"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"B10","first-page":"112","author":"Blum KA","year":"2008","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.857.857"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.8572"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404959"},{"key":"B16","first-page":"1136","volume":"9","author":"Ma MH","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701694194"},{"key":"B19","first-page":"106","author":"Hrusovsky I","year":"2005","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.106"},{"key":"B22","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner R","year":"2004","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-025809"},{"key":"B27","first-page":"S16","volume":"2","author":"Orlowski RZ","year":"2004","journal-title":"J Natl Compr Canc Netw"},{"key":"B28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"Kahl BS","year":"2010","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.079"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.483302"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.924.924"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2010.32.1844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:56:19Z","timestamp":1712670979000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.32.1844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":32,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2011,9,1]]}},"alternative-id":["10.1200\/JCO.2010.32.1844"],"URL":"https:\/\/doi.org\/10.1200\/jco.2010.32.1844","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,1]]}}}